| Drug General Information |
| Drug ID |
D05EML
|
| Former ID |
DNC011500
|
| Drug Name |
1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H26N2O2
|
| Canonical SMILES |
C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4
|
| InChI |
1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)
|
| InChIKey |
LQQIVYSCPWCSSD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Muscarinic acetylcholine receptor M3 |
Target Info |
Inhibitor |
[1]
|
|---|
| Muscarinic acetylcholine receptor M2 |
Target Info |
Inhibitor |
[1]
|
| Muscarinic acetylcholine receptor M1 |
Target Info |
Inhibitor |
[1]
|
| Muscarinic acetylcholine receptor M5 |
Target Info |
Inhibitor |
[1]
|
| Muscarinic acetylcholine receptor M4 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Cholinergic synapse
|
|
Regulation of actin cytoskeleton
|
|
Insulin secretion
|
|
Salivary secretion
|
|
Gastric acid secretion
|
|
Pancreatic secretionhsa04020:Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Regulation of actin cytoskeletonhsa04020:Calcium signaling pathway
|
|
Regulation of actin cytoskeletonhsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
|
PathWhiz Pathway
|
Gastric Acid ProductionPW000564:Muscle/Heart Contraction
|
|
Reactome
|
Muscarinic acetylcholine receptors
|
|
Acetylcholine regulates insulin secretion
|
|
G alpha (q) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
|
G alpha (i) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Regulation of Actin Cytoskeleton
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP706:SIDS Susceptibility Pathways
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Secretion of Hydrochloric Acid in Parietal Cells
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
| References |
| REF 1 | J Med Chem. 1989 May;32(5):1057-62.Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. |
|---|
